Gilead Sciences, Inc.

Chienhung Chou

Gediminas J Brizgys

James G Taylor

Nathan E Wright

Jeromy J Cottell

Zheng-Yu Yang

Elbert Chin

Sheila M Zipfel

Stephen E Ammann

Elizabeth M Bacon

Scott D Schroeder

Chao-I Hung

Marilyn Ndukwe

Jennifer R Zhang

Winston C Tse

John O Link

Michael Graupe

James S Cassidy

Kavoos Kolahdouzan

Jiayao Li

Qiaoyin Wu

Roland D Saito

Rhiannon Thomas-Tran

Michael L Mitchell

Eda Y Canales

Nathan D Shapiro

Suzanne M Szewczyk

Marina Shatskikh

William John Watkins

Scott E Lazerwith

Darryl Kato

Daniel G Shore

Megan K Armstrong

Gary Bruce Phillips

Thorsten A Kirschberg

Gregory Notte

Musong Kim

Adam James Schrier

Neil H Squires

David W Lin

Hang Chu

Julie Farand

Gayatri Balan

Yifan Deng

Prasenjit Kumar Mukherjee

James B C Mack

Tezcan Guney

Laurent P Debien

Ezra Roberts

Dong Min Mun

Shaina V Nguyen

Joshua D Farr

Daniel Roa

Pancham Lal Gupta

Katie A Spence

Benjamin J June

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

Capsid inhibitors for the treatment of HIV

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Therapeutic compounds

Growing community of inventors

Dublin, CA, United States of America

Chienhung Chou